Merck's manufacturing information not trade secrets, court rules

Merck Frosst Canada ($MRK) has reached the end of the legal line in its fight over whether manufacturing and clinical study information the company gave Health Canada were trade secrets protected from release to competitors under Canada's access-to-information law. Merck provided the information on Singulair, an asthma drug that it ultimately removed from the market, as part of the compliance process with the government's Food and Drug Regulations. When competitors asked for the information, and Health Canada agreed to provide it, Merck cried foul. It sued claiming competitors could piece together enough from the data to gain a competitive advantage. The Supreme Court upheld a lower court's ruling that the information was not protected. News | Pharmalot's take

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.